Menu
  • Join
  • Login
  • Contact
 

Search abstracts / presentations


Fetal transfer of Tadalafil is limited by breast cancer resistant protein in the mouse

  • At: Seville (Spain) (2022)
  • Type: Poster
  • Poster code: CBS-008
  • By: NISHIMURA, Tomohiro (Division of Pharmaceutics, Faculty of Pharmacy, Keio Univerisity, Japan)
  • Co-author(s): Dr Tomohiro Nishimura (Division of Pharmaceutics, Faculty of Pharmacy, Keio Univerisity, Tokyo, Japan)
    Ms Mari Ishii (Division of Pharmaceutics, Faculty of Pharmacy, Keio Univerisity, Tokyo, Japan)
    Dr Hiroaki Tanaka (Department of Obstetrics and Gynecology, Mie University Graduate School of Medicine, Tsu,, Japan)
    Dr Saki Noguchi (Division of Pharmaceutics, Faculty of Pharmacy, Keio Univerisity, Tokyo, Japan)
    Professor Tomoaki Ikeda (Department of Obstetrics and Gynecology, Mie University Graduate School of Medicine, Tsu,, Japan)
    Professor Masatoshi Tomi (Division of Pharmaceutics, Faculty of Pharmacy, Keio Univerisity, Tokyo, Japan)
  • Abstract:

    Background: Tadalafil, a phosphodiesterase 5 (PDE5) inhibitor, is expected to be a therapeutic agent for fetal growth restriction and hypertensive disorders of pregnancy, and it is under the clinical study. A perfusion study using human placenta suggested that tadalafil is less transferred to the fetus than sildenafil. The fetal transfer across..

  • The access to the whole abstract and if available the presentation file is available to FIP members and to congress participants of that specific congress. Please login
Last update 28 September 2023

FIP Congresses